Lupin Share Price Target 2026: Analyst Forecast, Bull & Bear Case

Thu Apr 09 2026

Lupin (NSE: LUPIN) is trading at Rs 1,880 as of April 2026, against a 52-week high of undefined and a 52-week low of undefined. The analyst consensus 12-month Lupin share price target stands at Rs 2,200-2,500 — implying meaningful upside from current levels. This article covers the current share price, key catalysts, risks, technical support levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term share price targets.

Table of Contents

Current Price Overview

Metric	Value
Current Market Price (CMP)	Rs 1,880
52-Week High	undefined
52-Week Low	undefined
Market Cap	Rs 85,600 Cr
P/E Ratio	26x
12M Analyst Target	Rs 2,200-2,500
Bull Case	Rs 2,800
Bear Case	Rs 1,400

About Lupin

Click Here – Get Free Investment Predictions

Lupin (NSE: LUPIN) is a leading listed company in the Pharma sector with a market capitalisation of Rs 85,600 Cr. The company operates across its core business segments and is well-positioned for the Indian economic growth cycle.

Key Catalysts Driving Lupin Share Price

1. US Specialty — Spiriva Respimat Generic

2. Lupin’s generic Spiriva Respimat (tiotropium) has first-to-file exclusivity in the US for a product with Rs 1,500-2,000 crore quarterly peak revenue potential. Launch timing depends on patent litigation outcome — a positive ruling would be a major positive catalyst.

3. Biosimilar Pegfilgrastim — Nyvepria

4. Lupin’s Nyvepria (pegfilgrastim biosimilar) is gaining market share in the US — the global G-CSF market is approximately $2.5 billion. Each percentage point of market share represents approximately Rs 200-250 crore revenue.

5. India Branded Business Recovery

6. Lupin’s India branded formulations — Ondero (Linagliptin), Gluconorm (Metformin), Rosuvast — are growing at 10-12% as the branded generic market recovers post-COVID disruption.

7. Japan Generic Market — Lupin’s Global Differentiation

8. Lupin has a meaningful Japan generics business (Rs 800-1,000 crore revenue) — rare among Indian pharma. Japan’s generic market is growing at 5-7% as the government promotes generic substitution.

Key Risks to Lupin Share Price

Spiriva litigation adverse outcome delaying US launch:

Pegfilgrastim biosimilar pricing pressure from Amgen Neulasta:

India branded margin pressure from channel destocking:

FDA inspection risk:

The 26% US reciprocal tariff on Indian goods — announced April 2, 2026 — has created a macro overhang affecting all Indian equities through FII outflows and earnings estimate revisions. Resolution of tariff uncertainty would be a meaningful positive catalyst for re-rating.

Technical Analysis and Support Levels

Lupin is trading at Rs 1,880 vs. a 52-week range of undefined to undefined. Key technical support is at Rs 1,780-2,000. The 200-day moving average provides medium-term guidance for trend direction.

Download the Univest iOS App or Univest Android App to track Lupin’s live price and get daily research insights.

Latest Quarterly Financial Performance

Key Metric	Latest Quarter	Year-Ago Quarter	YoY Change
Revenue	Rs 5,482 Cr	Rs 4,748 Cr	+15.5%
Net Profit	Rs 748 Cr	Rs 564 Cr	+32.6%
EBITDA Margin	22.8%	20.4%	+240 bps
US Revenue	Rs 2,420 Cr	Rs 2,080 Cr	+16.3%

Track Lupin’s live financials on Univest Screener

Institutional Positioning — FII, DII, Promoter

Promoter holds 46.9%. FII holding is 16.4% and DII holds 14.2%. Institutional holding trends are a critical leading indicator for price direction. Rising FII holding typically precedes price recovery; declining FII signals ongoing caution. Track institutional flow changes on Univest Screener.

Lupin Share Price Target 2026

Subscribe to Univest Pro for Premium Stock Research and F&O Setups

Short-Term Target (3–6 Months)

Short-term support and trading range: Rs 1,780-2,000. In the near term, the stock is likely to remain in this band pending clarity on Q4 FY26 results and FY27 guidance. Any macro positive from India-US tariff negotiations would accelerate a move toward the upper end of this range.

12-Month Analyst Target

The 12-month analyst consensus for Lupin is Rs 2,200-2,500. The bear case — if FY27 guidance disappoints or macro headwinds intensify — is Rs 1,400. The bull case — on full earnings delivery and macro recovery — is Rs 2,800. These are analyst estimates based on publicly available data and may differ materially from actual price performance.

Long-Term Target (2027–2028)

For 2027-2028, analysts project Lupin toward the Rs 3,000-3,500 range — assuming FY27 guidance delivery and normalisation of macro headwinds. Track live targets on Univest Screener.

Conclusion

The Lupin share price target for 2026 is Rs 2,200-2,500 based on analyst consensus. The bear case is Rs 1,400 and the bull case is Rs 2,800. At Rs 1,880, Lupin is trading at 26x P/E with market cap of Rs 85,600 Cr. Whether this is a buy depends on your risk tolerance, investment horizon, and portfolio context. For more share price target analysis, visit

Univest Blogs

Disclaimer: This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.

FAQs

Q1. What is Lupin share price target for 2026?

The 12-month analyst consensus is Rs 2,200-2,500. Bull case: Rs 2,800. Bear case: Rs 1,400.

Q2. Is Lupin a good buy at Rs 1,880?

At 26x P/E and Rs 1,880, Lupin offers potential recovery to Rs 2,200-2,500 over 12 months. Consult a SEBI-registered financial advisor before investing.

Q3. What are the key risks for Lupin?

Key risks include macro headwinds from US tariffs, sector-specific challenges, and any guidance miss in Q4 FY26 results. Monitor institutional holding trends on Univest Screener.

Q4. What is Lupin long-term share price target?

Long-term target for FY28 is Rs 3,000-3,500, contingent on sustained earnings delivery and macro recovery.